Survival for insulinoma

Insulinoma is a type of neuroendocrine tumour (NET) that starts in the insulin making cells of the pancreas. Survival for insulinomas depends on different factors. So no one can tell you exactly how long you will live.

Doctors usually work out the outlook for a certain disease by looking at large groups of people. Because insulinomas are so rare, the survival for this disease is harder to estimate than for other, more common cancers.

These are general statistics based on small groups of people. Remember, they can’t tell you what will happen in your individual case. Your specialist doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

What affects survival

Survival depends on many factors. It depends on the stage and grade of the insulinoma when it was diagnosed and your overall health. The stage describes the size of the cancer and whether it has spread. The grade means how abnormal the cells look under a microscope. 

Survival for insulinomas

There are no UK wide survival statistics for people with insulinoma. The statistics below are from a study in England and Wales.

Around 50 out of every 100 people (around 50%) diagnosed with insulinoma survive their cancer for 5 years or more.

Survival for NETs of the pancreas

1 year survival

The information below is for 1 year overall survival for pancreatic neuroendocrine neoplasms (NENs) in the UK.

Around 80 in 100 people (around 80%) survive for 1 year or more.

5 year survival

There are no UK-wide 5 year survival statistics available for pancreatic NENs. The statistics below are from a European study. Please be aware that these figures may not be a true picture of survival in the UK. This is due to differences in health care systems, data collection and the population,

Around 40 out of 100 people (around 40%) survive their cancer for 5 years or more after diagnosis.

About these statistics

The terms 1 year, 5 year and 10 year survival don't mean that you will only live for 1, 5 or 10 years.

The Office for National Statistics (ONS) and researchers collect information. They watch what happens to people with cancer in the years after their diagnosis. 5 or 10 years is a common time point to measure survival. But some people live much longer than this.

5 or 10 year survival is the number of people who have not died from their cancer within 5 or 10 years after diagnosis.

What next?

You might want to read our information about treatment for insulinomas. 

This page is due for review. We will update this as soon as possible.

  • Malignant insulinoma: recommendations for characterisation and treatment
    E Baudin and others
    Annals of Endocrinology, 2013. Vol 74, Issue 3, Pages 168-173

  • Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
    T Genus and others
    British Journal of Cancer (2019) Volume 121, pages 966–972

  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
    T Halfdanarson and others
    Annals of Oncology, 2008. Vol 19, Pages 1727-1733 

  • ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
    M Falconi and others
    Neuroendocrinology, 2016. Vol103, Pages 153–171

  • Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project
    J Maartaen Van de Zwan and others
    European Journal of Cancer, 2013 Volume 49, Issue 11 , Pages 2565-2578

  • Survival from malignant digestive endocrine tumors in England and Wales: a population-based study
    C Lepage and others
    Gastroenterology 2007, Volume 132, Issue 3, Pages 899-904.

Last reviewed: 
23 Jun 2022
Next review due: 
23 Jun 2025

Related links